Literature DB >> 10706879

Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure.

R R West1, D A Stafford, A D White, D T Bowen, R A Padua.   

Abstract

Patients with myelodysplastic syndromes (MDS) have high frequencies of cytogenetic abnormalities and evidence is accumulating of associations between exposure history and primary MDS. The objective of this article is to examine the relationship between histories of occupational or environmental exposure and presence of cytogenetic abnormalities. A case control study of MDS patients estimated lifetime exposure to more than 90 potential hazards in 400 age, sex, and area of residence matched patient and control pairs. A parallel cytogenetics study undertaken at time of diagnosis, independently of any knowledge of exposure history, identified 75 cytogenetically abnormal and 139 normal (186 not studied). Odds ratios of MDS patients and their matched controls were compared for 3 groups: cytogenetically abnormal, normal, and not known. The odds ratios for all exposures combined were possibly higher among cytogenetically abnormal 2.0 (95% confidence interval 0.8-5.9) than among normal 1.0 (0.6-1.8). This pattern was observed for exposure to semimetals, abnormal 4.0 (0.4-195.1) and normal 0.5 (0.1-1.0) and inorganic dusts, 1.6 (0. 6-3.8) and 0.4 (0.1-1.4) respectively. The pattern was principally in abnormalities in chromosomes 5 and 7. For organic chemicals and radiation, the odds ratios for both cytogenetically abnormal and normal were marginally raised: organic 1.8 (0.6-6.0) and 1.3 (0.6-2.9), respectively, and radiation 1.7 (0.5-5.6) and 1.3 (0.4-4.7) respectively. For radiation, abnormalities were mostly in chromosome 8. This study of association between exposures and cytogenetics in primary MDS complements those previously reported in secondary MDS and may provide some insight into pathogenetic mechanisms that lead to development of MDS. (Blood. 2000;95:2093-2097)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706879

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Telomere length in myelodysplastic syndromes.

Authors:  Dana E Rollison; P K Epling-Burnette; Jong Y Park; Ji-Hyun Lee; Hyun Park; Kristen Jonathan; Ashley L Cole; Jeffrey S Painter; Mayenha Guerrier; Johana Meléndez-Santiago; William Fulp; Rami Komrokji; Jeffrey Lancet; Alan F List
Journal:  Leuk Lymphoma       Date:  2011-06-03

2.  Association between occupational exposure to benzene and chromosomal alterations in lymphocytes of Brazilian petrochemical workers removed from exposure.

Authors:  Rozana Oliveira Gonçalves; Neli de Almeida Melo; Marco Antônio Vasconcelos Rêgo
Journal:  Environ Monit Assess       Date:  2016-05-07       Impact factor: 2.513

Review 3.  Important features of myelodysplastic syndrome.

Authors:  Wolf K Hofmann; H Phillip Koeffler
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

Authors:  Antonio C Wolff; Amanda L Blackford; Kala Visvanathan; Hope S Rugo; Beverly Moy; Lori J Goldstein; Keith Stockerl-Goldstein; Leigh Neumayer; Terry S Langbaum; Richard L Theriault; Melissa E Hughes; Jane C Weeks; Judith E Karp
Journal:  J Clin Oncol       Date:  2014-12-22       Impact factor: 44.544

Review 5.  Chromosome and molecular abnormalities in myelodysplastic syndromes.

Authors:  Pierre Fenaux
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

6.  Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.

Authors:  Wei Du; Xu-E Li; Jared Sipple; Qishen Pang
Journal:  Blood       Date:  2011-02-17       Impact factor: 22.113

7.  Evaluation of genotoxic effects of benzene and its derivatives in workers of gas stations.

Authors:  Patrícia Trevisan; Juliane Nascimento da Silva; Alessandra Pawelec da Silva; Rafael Fabiano Machado Rosa; Giorgio Adriano Paskulin; Flávia Valladão Thiesen; Ceres Andréia Vieira de Oliveira; Paulo Ricardo Gazzola Zen
Journal:  Environ Monit Assess       Date:  2013-11-30       Impact factor: 2.513

Review 8.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

Review 9.  Oxidative stress in Fanconi anemia hematopoiesis and disease progression.

Authors:  Wei Du; Zsuzsanna Adam; Reena Rani; Xiaoling Zhang; Qishen Pang
Journal:  Antioxid Redox Signal       Date:  2008-11       Impact factor: 8.401

Review 10.  TNF-α signaling in Fanconi anemia.

Authors:  Wei Du; Ozlem Erden; Qishen Pang
Journal:  Blood Cells Mol Dis       Date:  2013-07-24       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.